Jazz’s CNS Pipeline Demonstrates Transformation

 
• By David Wild
  
Generate a summary of this article
Listen to this article
Beta

With a first-in-class cannabis-derived treatment for epilepsy, a market-leading treatment for sleep disorders and now a foray into movement disorders, Jazz’s CNS pipeline is strong.

CNS Pills Bottle
Jazz Pharmaceuticals' CNS Pipeline Is Growing • Source: Zhanna Hapanovich

In an illustration of Jazz Pharmaceuticals plc’s focus on central nervous system disorders, the company recently presented 13 posters and oral presentations at the American Academy of Neurology annual meeting. The data, which largely buttress already-approved agents, ranged from describing the real-world impact of Xywav (calcium, magnesium, potassium and sodium oxybates) on idiopathic hypersomnia (IH) patients, to the long-term efficacy of its cannabis-derived Epidiolex (cannabidiol) on treatment-resistant epilepsies.

The data collectively paint a picture of a significant corporate shift, Phil Jochelson, Jazz’s neuroscience therapeutic head, told In Vivo.

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Intelligence

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-MarketIntelligence (Premium-2): Neuroanatomy of the Cerebral Cortex: Structure, Function, and Significance

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By Nabil

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge

 
• By David Wild

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.